Age-related macular degeneration will affect 1 in 4 older adults in Europe by 2050


  • Mary Corcoran
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

A new analysis suggests that the number of people affected by age-related macular degeneration (AMD) in the European Union (EU) will rise from 67 to 77 million by 2050. 

In a new study, published in the British Journal of Ophthalmology, researchers assessed the prevalence and incidence of AMD and calculated population-based estimates of future burden until the year 2050 in the European population. 

After examining data from 22 prevalence and four incidence studies, the authors reported that early and intermediate pooled prevalence estimates ranged from 9.3 per cent in those aged ≤64 years to 26.9 per cent in those over 75 years, with a prevalence of 25.3 per cent in all age groups combined. For any late AMD, pooled prevalence ranged from 0.3 per cent to 6.4 per cent, with a prevalence of 2.4 per in all age groups combined. 

The annual incidence of any late AMD was 0.5 per 1,000 in the age group of

The authors cautioned that the increasing numbers of incident and prevalent cases “will require considerable additional healthcare service and resource allocation, which should be considered already today in all European healthcare systems."